Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to 海角破解版 Technologies Canada Inc. and its subsidiaries and affiliates (“海角破解版”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the ?and??apply.
Easily isolate or deplete human CD11b+ cells from fresh or previously frozen peripheral blood mononuclear cells (PBMCs) or leukapheresis samples, using immunomagnetic positive selection, with the EasySep? Human CD11b Positive Selection and Depletion Kit. Widely used in published research for more than 20 years, EasySep? combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.
In this EasySep? positive selection procedure, cells of interest are labeled with antibody complexes recognizing CD11b and magnetic particles. Labeled cells are separated using an EasySep? magnet and by simply pouring off the unlabeled cells. The CD11b+ cells remain in the tube. Following magnetic cell isolation in as little as 16 minutes, desired cells from either fraction are ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction. This kit targets human CD11b, a subunit of the integrin macrophage-1 antigen (Mac-1) receptor commonly used as a myeloid cell marker. CD11b is expressed on immune cells such as monocytes, macrophages, neutrophils, and NK cell subsets, and is known to play a role in regulating cell adhesion, migration, and phagocytosis ().
Learn more about how immunomagnetic EasySep? technology works or how to fully automate immunomagnetic cell isolation with RoboSep?. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
Magnet Compatibility
? EasySep? Magnet (Catalog #18000)
? “The Big Easy” EasySep? Magnet (Catalog #18001)
? EasyEights? EasySep? Magnet (Catalog #18103)
? Easy 50 EasySep? Magnet (Catalog #18002)
? RoboSep?-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
Granulocytes and Subsets, Macrophages, Monocytes, NK Cells
Figure 1. Typical EasySep? Human CD11b+ Positive Selection Profile
Starting with human PBMCs, the CD11b+ cell content of the isolated fraction is typically 98.6 ± 1.4% after positive selection and 1.7 ± 1.2% after depletion (mean ± SD using the EasySep? magnet). In the above example, the frequencies of CD11b+ cells in the start, final isolated, and final depleted fractions are 47.8%, 99.4%, and 1.6%, respectively.
This product is designed for use in the following research area(s) as part
of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we
offer to support each research area.
Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis.
V. K. Singh et al.
Frontiers in immunology 2022
Abstract
Tuberculosis is a leading cause of death in mankind due to infectious agents, and Mycobacterium tuberculosis (Mtb) infects and survives in macrophages (M?¤s). Although M?¤s are a major niche, myeloid-derived suppressor cells (MDSCs) are an alternative site for pathogen persistence. Both M?¤s and MDSCs express varying levels of leukocyte immunoglobulin-like receptor B (LILRB), which regulate the myeloid cell suppressive function. Herein, we demonstrate that antagonism of LILRB2 by a monoclonal antibody (mab) induced a switch of human MDSCs towards an M1-macrophage phenotype, increasing the killing of intracellular Mtb. Mab-mediated antagonism of LILRB2 alone and its combination with a pharmacological blockade of SHP1/2 phosphatase increased proinflammatory cytokine responses and phosphorylation of ERK1/2, p38 MAPK, and NF-kB in Mtb-infected MDSCs. LILRB2 antagonism also upregulated anti-mycobacterial iNOS gene expression and an increase in both nitric oxide and reactive oxygen species synthesis. Because genes associated with the anti-mycobacterial function of M1-M?¤s were enhanced in MDSCs following mab treatment, we propose that LILRB2 antagonism reprograms MDSCs from an immunosuppressive state towards a pro-inflammatory phenotype that kills Mtb. LILRB2 is therefore a novel therapeutic target for eradicating Mtb in MDSCs.
Mouse monoclonal IgG1 antibody against human, rhesus, cynomolgus CD11b
Item added to your cart
EasySep? Human CD11b Positive Selection and Depletion Kit
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT 海角破解版, REFER TO WWW.海角破解版.COM/COMPLIANCE.
